Scholarlink

<p>The mRNA lipid nanoparticle (mRNA-LNP) is a promising platform for vaccines and a variety of therapeutic areas, as demonstrated by the effective mRNA-LNP formulations in COVID-19 vaccines. While <i>in-vitro</i> transfection studies are crucial for optimizing mRNA-LNP formulations, few studies examine how cell line selection and reporter genes affect transfection efficiency. In our study, we investigated the <i>in-vitro</i> transfection efficiency of firefly luciferase mRNA-LNP on Jurkat cells, L-929 cells, and HEK 293&#xa0;T cells. Jurkat cells, as a suspension cell line, displayed low transfection efficiency. The luciferase expression showed a non-linear relationship with mRNA dose, and cytotoxicity was observed with even low concentrations of mRNA. L-929 cells showed a linear relationship between bioluminescence and mRNA concentration, but only at low levels of mRNA, and their luciferase expression is limited. HEK 293&#xa0;T cells are superior because of a strong linear dose–response and higher signal intensity. However, when using the luciferase-based assay for mRNA-LNP transfection, we observed high intra-group variations with signal fluctuated among technical replicates of the same formulation. In contrast, eGFP mRNA exhibited high reproducibility for the <i>in-vitro</i> transfection tests (coefficient of variation &lt; 10%) and maintained strong linear correlation between mRNA concentration and eGFP expression (R<sup>2</sup> &gt; 0.95). This study highlights the importance of selecting a cell line model, a reporter gene, and analytical methods for developing a robust and reproducible <i>in-vitro</i> transfection assay for the development of mRNA-LNP formulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of cell line and reporter gene selection on in-vitro transfection evaluation of mRNA lipid nanoparticles

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Zixuan Zhen,
  • Xinhao Lin,
  • Mittal Darji,
  • Nirnoy Dan,
  • Sheyda Ranjbar,
  • Xiuling Lu

摘要

The mRNA lipid nanoparticle (mRNA-LNP) is a promising platform for vaccines and a variety of therapeutic areas, as demonstrated by the effective mRNA-LNP formulations in COVID-19 vaccines. While in-vitro transfection studies are crucial for optimizing mRNA-LNP formulations, few studies examine how cell line selection and reporter genes affect transfection efficiency. In our study, we investigated the in-vitro transfection efficiency of firefly luciferase mRNA-LNP on Jurkat cells, L-929 cells, and HEK 293 T cells. Jurkat cells, as a suspension cell line, displayed low transfection efficiency. The luciferase expression showed a non-linear relationship with mRNA dose, and cytotoxicity was observed with even low concentrations of mRNA. L-929 cells showed a linear relationship between bioluminescence and mRNA concentration, but only at low levels of mRNA, and their luciferase expression is limited. HEK 293 T cells are superior because of a strong linear dose–response and higher signal intensity. However, when using the luciferase-based assay for mRNA-LNP transfection, we observed high intra-group variations with signal fluctuated among technical replicates of the same formulation. In contrast, eGFP mRNA exhibited high reproducibility for the in-vitro transfection tests (coefficient of variation < 10%) and maintained strong linear correlation between mRNA concentration and eGFP expression (R2 > 0.95). This study highlights the importance of selecting a cell line model, a reporter gene, and analytical methods for developing a robust and reproducible in-vitro transfection assay for the development of mRNA-LNP formulation.